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Abstract
Dementia with Lewy bodies (DLB) represents a hugemedical need as it accounts for up to 30% of all dementia cases, and there is
no cure available. The underyling spectrum of pathology is complex and creates a challenge for targeted molecular therapies. We
here tested the hypothesis that leukotrienes are involved in the pathology of DLB and that blocking leukotrienes through
Montelukast, a leukotriene receptor antagonist and approved anti-asthmatic drug, might alleviate pathology and restore cognitive
functions. Expression of 5-lipoxygenase, the rate-limiting enzyme for leukotriene production, was indeed elevated in brains with
DLB. Treatment of cognitively deficient human alpha-synuclein overexpressing transgenic mice with Montelukast restored
memory. Montelukast treatment resulted in modulation of beclin-1 expression, a marker for autophagy, and in a reduction in
the human alpha-synulcein load in the transgenic mice. Reducing the protein aggregation load in neurodegenerative diseases
might be a novel model of action ofMontelukast. Moreover, this work presents leukotriene signaling as a potential drug target for
DLB and shows that Montelukast might be a promising drug candidate for future DLB therapy development.
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Introduction
Dementia with Lewy bodies (DLB) and Parkinson’s disease
dementia (PDD) are age-related chronic neurodegenerative
syndromes with the common features of cognitive decline,
parkinsonian motor symptoms, and with an underlying pa-
thology of alpha-synuclein aggregated in neuronal inclusions,
so called Lewy bodies [1, 2]. The two syndromes are roofed
under the term Lewy body dementias (LBD) [2]. DLB and
PDD differ in the sequence of onset of symptoms, as in DLB,
cognitive deficits preceed the parkinsonian motor symptoms,
whereas in PDD, the motor symptoms arise at least 1 year
before the cognitive decline. The cognitive deficits and its
consequences for the patients rank as one of the key unmet
needs of LBD therapy [3]. This is further underscored by the
fact that LBD comprises, after Alzheimer’s disease, the sec-
ond most common type of degenerative dementia in patients
older than 65 years. Currently available symptomatic treat-
ments such as cholinesterase inhibitors have limited efficacy
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in improving cognition and show significant side effects [4].
The efficacy of disease-modifying approaches remains to be
demonstrated [5, 6].
The exact molecular and cellular basis for the cognitive
impairment in LBD is only partially understood [7].
Neuronal cell death [8], which is triggered by multiple factors
such as alpha-synuclein fibrils [9], reduced levels of
neurogenesis [10], impaired neuronal autophagy [11] and ly-
sosomal dysfunctions [12], and neuroinflammation [13] trig-
gered by microglia dysfunctions [14], have been implicated in
LBD. We hypothesize that therapeutic approaches addressing
a spectrum of these neuropathological aspects, eventually
through a pleiotropic mode of action, might have a chance
of improving cognitive functions in LBD, and may be more
promising thanmonospecific and single mode of action drugs.
One of the molecular signaling systems that is implicated in
a number of pathological hallmarks of chronic neurodegenera-
tive diseases such as LBD is leukotriene signaling (for review,
see [15]). In the aged and neurodegenerative brain, cysteinyl-
leukotrienes (Cys-LTs) contribute to neuroinflammation, en-
hance neurodegeneration, induce BBB disruption, and inhibit
neurogenesis. Cys-LTs act via signaling through leukotriene
receptors CysLT1R, CysLT2R, and GPR17, which are
expressed in the brain, in particular on endothelial cells, microg-
lia, neurons, and on stem and progenitor cells [16–18]. Genetic
modulation of the leukotriene system has been performed in the
context of Alzheimer’s disease (AD) models. There, elevated
leukotriene levels exaggerate disease pathology and cognitive
dysfunctions, and vice versa, blocking leukotriene signaling
reduces pathology and improves cognitive functions (for re-
view [15]). In consequence, there is increasing evidence sug-
gesting that leukotriene receptor antagonists might be potential
drug candidates to improve cognition in dementias. For exam-
ple, we have recently shown that the Cys-LTR1 and GPR17
leukotriene receptor antagonist Montelukast, an approved anti-
asthma drug, elevates neurogenesis, reduces neuroinflamma-
tion, restores BBB integrity, and improves learning and mem-
ory in aged rodents, which show cognitive imparments [19].
Also, in various other animal models of neurodegenerative dis-
eases, including a model of kainic acid-induced loss of memory
function, an acute Huntintgon’s disease model of quinolinic
acid and malonic acid injection-induced degeneration of striatal
neurons, anβ-amyloid injectionmodel of AD, a streptozotozin-
induced model of cognitive decline, and in the MCAO stroke
model, treatment with Montelukast attenuated behavioral defi-
cits, which was accompanied by inhibition of neuroinflamma-
tion and reduced neuronal cell death [20–24]. Based on these
data, targeting the leukotriene system might be an interesting
therapeutic approach not only in Alzheimer’s disease [15], but
also in various other neurodegenerative diseases including
LBD.
At present, the leukotriene signaling system is completely
unexplored in the field of LBD. Moreover, it is unknown if
targeting leukotriene signaling might be able to alleviate
symptoms associated with LBD, in particular cognitive func-
tions. To explore that, we made use of the D-line PDGF-
promoter-driven human alpha-synuclein overexpressing
transgenic mouse model (alpha-syn mice) [25] and of human
post-mortem brain specimen with LBD. The alpha-syn mice
replicate features of human synucleinopathies such as abnor-
mal accumulation of alpha-synuclein, development of cogni-
tive impairments, and motor deficits. Interestingly, the cogni-
tive deficits preceed the motor deficits in this mouse model,
and therefore, the alpha-syn mice can be considered as a mod-
el for DLB [26]. We explored 5-Lox expression in the brains
of alpha-syn and wild-type (WT)mice and in human DLB and
age-matched control brains. Moreover, we tested the effects of
a 6-week treatment with the leukotriene receptor antagonist
Montelukast on neurogenesis, neuroinflammation, alpha-
synuclein load, autophagy, and most importantly on cognitive
functions in these mice.
Material and Methods
Human Brain Specimen
We used 7-μm hippocampal sections from formalin-fixed par-
affin-embedded brain samples which were obtained from the
Newcastle Brain Tissue Resource (NBTR) in accordance with
Newcastle University ethics board and ethical approval
awarded by The Joint Ethics Committee of Newcastle and
North Tyneside Health Authority (reference: 08/H0906/136).
Irrespective of clinical diagnoses, brains underwent neuro-
pathological examination according to a routine protocol that
uses standardized neuropathological scoring/grading systems,
including neurofibrillary tangle (NFT) Braak staging [27, 28],
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) scores [29], Newcastle/McKeith Criteria for Lewy
body disease [30], National Institute on Aging – Alzheimer’s
Association (NIA-AA) guidelines [31], and Thal phases of
amyloid β deposition [32].
Animals
Six-month-old female transgenic (TG) mice expressing hu-
man wild-type alpha-synuclein under the regulatory control
of the PDGFbeta promoter (D-line) [25] and their wild-type
(WT) litter mates as controls were used. Mice were housed at
the central animal facility at UCSD in groups under standard
conditions at a temperature of 22 °C and a 12-h light/dark
cycle with ad libitum access to standard food and water.
Animal care and handling were performed according to the
Declaration of Helsinki and in strict accordance with good
animal practice and all procedures were completed under the
J. Marschallinger et al.
specifications set forth by the UCSD Institutional Animal
Care and Use Committee.
Montelukast Pharmacoexposure Analysis
Six-month-old alpha-syn and WT mice (n = 12) received
Montelukast (10 mg kg−1 per day; dissolved in a 0.9%
NaCl solution containing 10% ethanol) via oral gavage
for seven consecutive days. One hour after the last ga-
vage, blood was collected from every individual and se-
rum was obtained by 1-h incubation of the blood sample
at 37 °C and subsequent centrifugation at 13000 rpm. The
supernatant was stored at − 20 °C until further processing.
Immediately after blood collection, the animals were
transcardially perfused with PBS to remove all blood from
the body. Afterwards, the brain was extracted, and all
tissue was stored at − 80 °C.
Mouse brains were homogenized with an equal weight of
water using a Bullet Blender (Next Advance). Aliquots of
homogenate from each sample were transferred to a 96 well
plate and 3 volumes of acetonitrile (Fisher) containing an in-
ternal standard (200 ng/mL tolbutamide, Sigma) were added
to each. After centrifugation (15 min at 1500g), supernatant
(50 μL) was transferred to another 96-well plate and 100 μL
of water added. Control brain tissue was treated in the same
way to provide blank samples and calibration standards by
spiking control brain homogenate with known amounts of
montelukast. CSF was prepared for analysis by dilution with
tolbutamide (200 ng mL−1) in acetonitrile; artificial CSF was
used as control matrix.
Samples were analyzed using an Agilent 1290 Infinity bi-
nary pump and autosampler with detection by anAgilent 6550
iFunnel QTof mass spectrometer (MS) (Agilent) using
electrospray ionization. The protonated molecules for
Montelukast and tolbutamide (m/z 586.2177 and m/z
271.1116) were extracted with ± 15 ppm mass windows to
generate chromatograms with suitable combinations of spec-
ificity and signal/noise. Sample aliquots (5 μL) were injected
into a mobile phase initially of 98% water/0.1% formic acid
(Channel A) and 2% acetonitrile/0.1% formic acid (Channel
B) delivered at 0.4 mL/min to an Acquity BEH C18 50 ×
2.1 mm, 1.7 μm column. The column was maintained at
50 °C in an Agilent Infinity column oven. The mobile phase
composition was programmed to change linearly from 2%
Channel B at 0.30 min post-injection up to 95% at 1.10 min,
maintained at 95% until 1.75 min, and then returning to initial
composition at 1.8 min. Column effluent was diverted to
waste for the first 0.8 min post-injection to minimize source
contamination. Data processing was carried out using
MassHunter software (v B.05.01, Agilent UK). Calibration
curves were fitted using the simplest regression model to min-
imize back-calculated calibration standard concentration re-
siduals over the range of study sample concentrations.
Montelukast Treatment
A total of 27 animals (8 TG vehicle, 8 TG Montelukast, 5
WT vehic le , 6 WT Monte lukas t ) were t rea ted .
Montelukast sodium powder (Sigma) was first dissolved
in ethanol for maximum solubility and then further diluted
(1:9 ratio) with a 0.9% saline (NaCl) solution. A 3 mg/ml
stock solution was prepared freshly every day and was
administered daily per oral gavage (p.o.) at a dose of
10 mg kg−1 of body weight for 42 days. Control mice
received volume-matched injections of the vehicle solu-
tion (10% ethanol in 0.9% NaCl).
Behavioral Tests
Twenty-eight days after starting the Montelukast treatment,
several standardized behavioral tests were carried out.
Spontaneous Locomotor Activity Spontaneous movements of
the mice were measured in a small, transparent cylinder
15.5 cm high and 12.7 cm in diameter. The cylinder was
placed on a piece of glass with a mirror positioned at an angle
beneath the cylinder to allow a clear view of movements along
the ground and walls. Spontaneous movements were recorded
for 3 min. Videotapes were viewed and rated in slow motion
by an experimenter blinded to mouse genotype. The number
of rears, forelimb and hindlimb steps, and time spent
grooming were determined for each mouse [33].
Open Field The open field locomotor test was used to deter-
mine basal activity levels of study subjects (total move time)
during a 15-min session. Spontaneous activity in an open field
(25.5 × 25.5 cm) was monitored for 15 min using an automat-
ed system (Truscan system for mice; Coulbourn Instruments).
Animals were tested within the first 2–4 h of the dark cycle
after being habituated to the testing room for 15min. The open
field was illuminated with an anglepoise lamp equippedwith a
25 W red bulb. Time spent in motion was automatically col-
lected in 3 × 5 min time bins using TruScan software. Data
were analyzed for both the entire 15-min session and for each
of the 5-min time blocks.
Spontaneous locomotor activity and open field parameters
were assessed using photocell emitters and receptors equally
spaced along the perimeter of the chamber, which create an x-
y grid of invisible infrared beams. Animals being placed in the
chamber move and cause beam breaks. Vertical sensors are
also present to assess vertical activity levels (i.e., rearing
behavior).
Fecal Motility Following the locomotor activity testing, fecal
pellets were collected from each mouse. The number of fecal
pellets per mouse was used as readout for fecal motility.
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Morris Water Maze On days 35–41 after the first
Montelukast administration, the water maze procedure
was used to assess the ability of spatial learning and mem-
ory. The apparatus consisted of a circular swimming pool
built of black plastic (180-cm diameter, 76-cm height),
filled with 21 °C ± 1 °C tempered water. The tank was
virtually divided into four equal quadrants, with a sub-
merged hidden 10 × 10 cm fiberglass platform placed
3 cm below the water surface in the middle of the target
quadrant. The position of the platform was kept unaltered
throughout the learning sessions. In the testing room, sev-
eral big black cue symbols were put on each wallfor spa-
tial orientation. The water maze task was carried out twice
a day for five consecutive days. One day before starting
the learning experiment (day 0), each mouse was put into
the water and was allowed to locate the submerged plat-
form for 60 s. If the animal failed to find the platform
within the 60 s, it was guided onto the platform and
allowed to remain there for 10 s. For the learning tasks
on days 1–5, each mouse was put into the water at one of
four starting positions, the sequence of which being se-
lected randomly. In each trial, a ceiling time of 60 s to
find the platform was defined. The escape latency time to
locate the hidden platform and the distance moved during
the trial were recorded with the camera software as indi-
ces of spatial learning. On the final day of testing (day 8),
after the learning phase of the experiment, a probe trial
was performed. Here, the platform was removed and each
animal was allowed to explore the pool for 60 s. The time
spent in the former platform zone (“correct zone”) was
recorded.
Perfusion and Tissue Processing
On day 42, mice were deeply anesthetized using a ketamine
(20.38 mg/ml), xylazine (5.38 mg/ml), and acepromazine
(0.29 mg/ml) mixture. Transcardial perfusion was performed
with 0.9% NaCl solution, followed by a 4% paraformalde-
hyde, 0.1 M sodium phosphate solution (pH 7.4). The brains
were dissected and post-fixed for 4 days in a 4% paraformal-
dehyde solution at 4 °C. Brains were cut using a sliding
microtom into 40-μm saggital sections on dry ice and then
cryoprotected in 30% sucrose, 0.1 M sodium phosphate solu-
tion (pH 7.4) and kept at − 20 °C.
Immunohistochemistry
Immunohistochemistry (IHC) of mouse tissue was performed
on free-floating sections as previously described [19]. Antigen
retrieval was performed depending on the used primary anti-
body by heating the sections for 15–20min in 1x citrate buffer
(pH = 6.0, Sigma).
Diaminobenzidine Staining
The following primary antibodies were used for chromogenic
IHC: rabbit anti-Doublecortin (1:300, Cell Signaling), goat
anti-Doublecortin (1:350, Santa Cruz), ms anti-5-LOX
(1:100, BD Transduction Laboratories), rabbit anti-Iba1
(1:300, Wako), goat anti-PCNA (1:250, Santa Cruz).
Secondary antibodies: donkey anti-mouse, anti-goat, anti-rab-
bit, anti-rat biotinylated (all 1:500, Jackson Immuno
Research). After incubation in secondary antibodies, sections
were incubated in Avidin-Biotin-Peroxidase solution
(Vectastain ABC Kit) and visualization was performed using
the diaminobenzidine (DAB) peroxidase substrate kit (SK-
4100, Vector Laboratories). All quantification of immunohis-
tochemistry was done blinded (i.e., the experimenter was not
aware of the group to which the analyzed material belonged).
Every tenth section (40-μm interval) of one hemisphere was
selected from each animal and processed for immunohisto-
chemistry. Cells positive for the respective marker (PCNA,
DCX, or Iba1) within the dentate gyrus were counted on a
Zeiss Axioplan microscope. To further analyze Iba1+ cells,
their soma size was measured in the GL and SGZ in 2 images
per mouse taken with a 20× objective. First, the cell somas
were traced manually in the GNU Image Manipulation
Program (GNU GIMP 2.6.11, www.gimp.org). Afterwards,
the size of the somas was measured with the “Analyze
Particles” function of the software ImageJ (ImageJ 1.45s,
National Institutes of Health, https://imagej.nih.gov/ij).
Fluorescence Staining
The following antibodies were used for fluorescence IHC: rat
anti alpha-synuclein (1:50, Enzo), mouse anti aggregated alpha-
synuclein clone 5G4 (1:500, Merck), rabbit anti NeuN (1:200,
Cell Signaling), rabbit anti Beclin-1 (1:500, Sigma), rabbit anti
Lamp2A (1:200, Abcam), guinea pig anti NeuN (1:500, Merck),
rabbit anti TSPO (1:250, Novus Biologicals), goat anti-Iba1
(1:500, Abcam), ms anti-5-LOX (1:50, BD Biosciences). For
alpha-synuclein staining, antibody incubation timewas increased
from 1× overnight to a total of 5 days on 4 °C. Sections were
extensively washed in PBS and incubated for 3 h at RT in sec-
ondary antibodies all diluted 1:1000. The following secondary
antibodies were used: donkey anti-rabbit Alexa Fluor 568 or
Alexa Fluor 647, donkey anti-goat Alexa Fluor 568, donkey
anti-rat Alexa Fluor 488 or Alexa Fluor 568 (all Invitrogen/
Molecular Probes), donkey anti-guinea pig, and donkey anti-
mouse Alexa Fluor 647 (Jackson Immuno Research). Nucleus
counterstaining was performed with 4′,6′-diamidino-2-
phenylindoledihydrochloride hydrate (DAPI 1 mg/mL, 1:2000,
Sigma). Sections were extensively washed in PBS and mounted
onto microscope glass slides (Superfrost Plus, Thermo
Scientific). Brain sections were cover slipped semi-dry in
ProLong Gold Antifade Mountant (Life technologies) or
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Fluorescence Mounting Medium (Dako). A confocal scanning
laser microscope (Zeiss LSM 700, Germany) equipped with the
Zeiss AxioVision imaging system,with the LSM software (ZEN
black 2011), was used for imaging of brain sections labeled with
fluorescent antibodies. TSPO/Iba1 staining: Four visual fields
(400 × 400 × 40 μm) of dentate gyrus in 40×magnification were
taken per animal. Percentage area of TSPO in the dentate gyrus
was measured with the help of ImageJ.
a-Syn/NeuN and 5-Lox staining Each slide contained sections
of a representative 10th of mouse hemisphere. Three different
sections containing triangle shaped dentate gyrus were select-
ed from each slide and z-stacks of two visual fields (400 ×
400 × 40 μm) in 20× magnification were taken in order to
photograph the whole dentate gyrus per section. Using
ImageJ, z-stack was merged to maximum projection and re-
gion of interest (ROI), containing dentate gyrus plus hilus,
was defined based on NeuN staining, or DAPI for analysis
of 5-Lox, respectively. Percentage area was measured in ROI,
also using ImageJ software. Additionally, a-Syn + cells were
counted in the same ROI. Thickness of DG was measured
based on Neun staining. Beclin1/NeuN and Lamp2A/NeuN
staining: ImageJ was used to identify the percentage area of
each autophagy-lysosomal pathway (ALP) marker, the auto-
fluorescence signal and the colocalization of both. The select-
ed ROI included only neurons of the granula layer of the
dentate gyrus. For each Beclin-I stained brain slice, a z-stack
of 5 slices was recorded and merged for analysis. For the
Lamp2a staining only the one most intensely stained picture
of the z-stack was used for analysis. To select valid, specific
immunostaining signals for every antibody, the threshold for
detection was adjusted individually on each merged picture.
Control brain slices were stained with secondary antibodies
only, to confirm specificity of the ALP marker staining. The
autofluorescence, recorded at 568 nm wavelength, was most
likely caused by age associated lipofuscin accumulations. To
avoid recording false positive ALP marker expression, the
autofluorescence co-staining signal was subtracted from the
ALP marker channel by using ImageJ.
FFPE Immunohistochemistry
Human samples were immunohistologically stained as follows:
formalin-fixed paraffin-embedded (FFPE) human tissue sec-
tions were deparaffinized by incubation in Roti®-Histol
(Roth-Lactan), rehydrated by a graded series of ethanol and
rinsed in distilled water for 5 min. For antigen retrieval, the
slides were heated in 0.01 M sodium citrate buffer, pH 6.0 at
100 °C for 25 min, followed by 3 washes in PBS + 0.1%
Tween. Endogenous peroxidases were quenched with 0.3%
hydrogen peroxide for 20 min. Sections were blocked with a
solution composed of PBS, 0.1% TWEEN 20 (Sigma), 1%
bovine serum albumin, and 0.2% teleostean gelatin (Sigma)
for 20 min, and incubated overnight at 4 °C with a mouse anti
5-LOX antibody (1:50; 610695, BD Pharmingen) diluted in the
blocking solution. After incubation, the sections were washed
in PBST, incubated with a biotinylated donkey anti-mouse an-
tibody (1:500, Jackson Immuno Research) for 1 h, washed in
PBST, and incubated for 1 h in a peroxidase-avidin complex
solution (Vectastain Elite ABC kit; Vector Laboratories). The
peroxidase activity of immune complexes was revealed with a
solution of PBS containing 0.25 mg/mL 3,3-diaminobenzidine
(Vector Laboratories), 0.01% H2O2, and 0.04% NiCl2.
Hematoxylin (RE7107-CE, Leica) was used for cell nuclei
counter stain. Sections were dehydrated by a graded series of
ethanol and mounted with Neo-Mount (Merck). VS120
Virtual-Slide-Mikroskop, 20× objective (Olympus) was used
for qualitative pictures of human tissue section.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
7.0 software (GraphPad Software). Normality distribution of
continuous variables was assessed by Shapiro-Wilk test.
Grubb’s test (p < 0.05) of QuickCals GraphPad Sotfware
(http://graphpad.com/quickcalcs/grubbs1) was used to
identify statistical outliers. Comparing two groups, the
unpaired Student’s t test was used. For comparing multiple
groups, one-way ANOVAwas used followed by Tukey’s mul-
tiple comparison test. For analysis of learning behavior over
time, two-way ANOVA followed by Sidak post hoc test was
used. Correlation analyses were performed using Pearson’s
correlation coefficient. p values of p < 0.001 (***) were con-
sidered most significant, p < 0.01 (**) highly significant, and
p < 0.05 (*) significant. All values were expressed as means ±
standard deviation (SD), unless otherwise stated.
Results
Increased 5-Lox Expression in DLB Brains
5-Lox is the key enzyme in the synthesis of leukotrienes and its
expression is indicative for leukotriene production. Here, we
analyzed 5-Lox immunoreactivity in post-mortem brains with
DLB and in brains of 6 months old transgenic alpha-syn mice
expressing human wild-type alpha-synuclein under the regula-
tory control of the PDGFbeta promoter [25] and wild-type
(WT) litter mates. At this age, the TG animals have already
cognitive deficits but do not suffer yet of motor impairments
[26]. In the human DLB brain, more specifically in the hippo-
campus, we noticed a strong 5-Lox immunoreactivity, although
only a faint signal was present in the age-matched control
(Fig. 1a). This was systematically and quantitatively assessed
in a set of 7 DLB brains and 5 healthy control brains (Table 1).
The analysis revealed a significantly higher level of 5-Lox
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immunoreactivity in the DLB brains (Fig. 1b). Similarly, we
detected in some animals a stronger 5-Lox immunoreactivity
in the hippocampus in the alpha-syn mice compared to WT
mice (Fig. 1c). This, however, was quite variable and did not
reach significance in 5 animals per group. Nevertheless, as the
human data are quite convincing, we suggest that leukotriene
synthesis migh be elevated in DLB brains.
Montelukast Treatment Improves Memory
in Alpha-Syn Mice
We had previously shown that a 6-week treatment with
Montelukast improved learning and memory in aged rats
[19]. Here, we made use of this treatment regimen to test the
effects of Montelukast on structural and functional outcomes in
the alpha-syn TG and WT animals. For that, 6 months old TG
mice and their WT litter mate controls were treated daily with
10 mg/kg Montelukast by oral gavage for a total period of
6 weeks. During the last 2 weeks of treatment, behavioral as-
sessments, i.e., spontaneous locomotor activity in an activity
cage and in the open field, autonoumous nervous system func-
tion indicated by fecal motility, and cognitive function in the
Morris water maze test were performed. At the end of the treat-
ment period, animals were perfused and brains were prepared
for immunohistological analyses (Fig. 2a). In a second cohort of
drug-treated animals, serum and brain tissue was analyzed for
the levels of Montelukast in the central nervous system of TG
and WT mice and to provide pharmacoexposure data.
As expected, we found high levels of Montelukast in the
range of 500 to 1000 ng/ml in the serum of WT and of TG
Fig. 1 5-Lox expression is upregulated in the hippocampus of DLB
brains. (a) + (b) DAB-5-Lox immunoreactivity in hippocampal neurons
in post-mortem brains of DLB patients compared to aged controls. (a)
The images show representative 5-Lox immunoreactivity of a 75-year-old
DLB patient and a 90-year-old healthy control. Note the stronger 5-Lox
immunoreactivity in the DLB brain compared to the control brain. (b) 5-
Lox DAB staining of 5–7 brains per group, one section each, were
quantitatively analyzed. Brain sections of patients with diagnosed DLB
showed significantly higher amount of 5-Lox than controls. (c)
Representative image of immunofluorescence 5-Lox staining in dentate
gyrus hippocampal neurons of 6-month-old alpha-syn and WT control
mice. Note the intensive 5-Lox immunoreactivity in the alpha-syn mice
compared to weak staining in theWT littermate controls. (d) Quantitative
analysis of 5-Lox staining in 6-month-oldmice, transgenic animals versus
wild-type (n = 5). Data are shown as mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.001. Unpaired Student’s t test was performed (b, d). Scale bars:
(a) 50 μm, (c) 200 μm
Table 1 Neuropathology of DLB cases
Pathologic diagnosis McKeith Age at death Gender
DLB Neocortical 81 Male
DLB Neocortical 81 Male
DLB Neocortical 83 Male
DLB Neocortical 75 Female
DLB Neocortical 79 Female
DLB Neocortical 81 Female
DLB Neocortical 91 Female
Nothing abnormal beyond age No LBD 70 Male
Nothing abnormal beyond age No LBD 73 Male
Nothing abnormal beyond age No LBD 73 Male
Nothing abnormal beyond age No LBD 90 Female
Nothing abnormal beyond age No LBD 93 Female
Pathological diagnosis, age, gender, andMcKeith Criteria for Lewy body
disease of hippocampal sections from formalin-fixed paraffin-embedded
brain samples which were obtained from the Newcastle Brain Tissue
Resource (NBTR) in accordance with Newcastle University ethics board
and ethical approval awarded by The Joint Ethics Committee of
Newcastle and North Tyneside Health Authority (reference: 08/H0906/
136)
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animals (Fig. 2b). Further, and in accordance with findings
from our previous work in rats [19], the levels of Montelukast
in the brain were much lower, approximately 10–20 ng/ml,
which however is in the range of the Montelukast IC50 and
therefore in the pharmacological active range [19].
Pharmacoexposure in WTand in TG animals were comparable
suggesting that the bioavailability of Montelukast in the TG
animals was not disturbed.
In a first set of behavioral tests, we assessed spontaneous
locomotor function and the effects of theMontelukast treatment
on this activity by analyzing the number of beam breaks in a
home cage. The 7.5 months old TG animals did not differ from
WT animals and Montelukast did not affect this parameter
(Supplementary Figure 1). This confirms that the TG animals
do not have a noticeable motor deficit at this age, andmoreover,
that Montelukast treatment does not induce any motor adverse
events. In the open field, the TG animals tended to spend less
time in the center zone of the arena and more time in the pe-
riphery suggesting that the TG animals might suffer from a
higher level of anxiety. This, however, did not reach
Fig. 2 Montelukast treatment improves memory in alpha-syn mice. (a)
Experimental design. (b) Pharmacoexposure data: 6-month-old alpha-syn
mice received daily 10 mg kg−1 Montelukast via oral gavage for seven
consecutive days. One hour after the last gavage, blood was drawn, brains
were removed, and levels of Montelukast were quantified. Montelukast
levels were in the expected range of approximately 500 to 1000 ng/ml in
the serum and 10–20 ng/ml in the brain of WT and of TG animals. (c–g)
Behavioral analyses. (c–e) open field: (c) total distance, alpha-syn
animals did not differ from WT animals, and Montelukast treatment did
not affect animals in these parameters. (d) % center distance: TG animals
tended to spend less time in the center zone of the arena and more time in
the periphery. Montelukast treatment did neither affect WT nor TG
animals in this parameter. (e) Fecal motility (FM), i.e., the number of
feces, demonstrates that the TG animals did not differ from WT
animals, but Montelukast treatment significantly increased the fecal
motility in both genotypes. (f, g) learning and memory were analyzed
in the Morris water maze: (f) Latency times to find the hidden platform.
Although vehicle treated WTanimals showed a steep learning curve, TG
animals failed to learn the location of the platform. Transgenic animals
learned significantly worse than wildtype animals. In contrast,
Montelukast treated TG animals showed a similar learning performance
compared to the WT animals. (g) Montelukast treated TG animals
significantly performed better than the vehicle treated animals and
reached a level of performance similar to the WT animals. Data are
shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. One-way
ANOVA followed by Tukey’s post hoc test (c–e, g), and two-way
ANOVAwith Sidak post hoc tests (f). N 4–5 per group
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significance. Montelukast treatment did neither affect WT nor
TG animals in this parameter (Fig. 2c, d).
We analyzed fecal motility, i.e., the number of feces, as an
indicator of bowel activity and autonomic nervous system
function, as reduced bowel activity is known to be one of
the symptoms in LBD [1]. The TG animals did not differ from
WT animals in fecal motility, but interestingly, Montelukast
treatment significantly increased the fecal motility in both ge-
notypes, i.e., WTand TG (Fig. 2e). Whether this is related to a
direct action ofMontelukast on the autonomic nervous system
or an unspecific side effect of Montelukast is unclear.
Irrespectively, it can be interpreted as a beneficial effect.
Finally, we assessed spatial learning and memory in the
Morris water maze. Compared to the vehicle treated WT ani-
mals, which showed strong learning already within the first
2 days of the experiment, the TG animals failed to learn the
location of the platform during the 7 days of the test. The
Montelukast treated alpha-syn animals showed a tendency for
increased learning compared to the vehicle treated ones, how-
ever, the improvement did not reach statistical significance (Fig.
2f). The Montelukast treated TG animals had nevertheless a
similar performance compared to the WT animals supporting
the efficacy of Montelukast to improve learning in this animal
model. On day 8, 1 day after the learning acquisition, animals
were tested in the probe trial for their capacity to remember the
location of the platform by analyzing the time the animals spent
in the zone where the platform used to be. Here, the
Montelukast treated TG animals performed remarkably better
than the vehicle treated animals and reached a level of perfor-
mance similar to the WTanimals. In summary, we confirm that
the TG animals at the age of 7 to 8 months do not have any
obvious motor deficits, but have severe cognitive deficits.
Montelukast did not induce any side effects neither in WT nor
in TG animals, but restored memory function in the TG mice.
Montelukast Treatment and Microglia in the Brains
of the DLB Animal Model
Based on our previous work, which showed neurogenesis
promoting effects of Montelukast in aged rats [19], we first
analyzed proliferating and doublecortin positive neural stem
and progenitor cells in the hippocampus of TG and WT ani-
mals and assessed the effects of Montelukast treatment on
neurogenesis. In contrast to a previous publication [34], the
alpha-syn TG mice did not show impaired hippocampal
neurogenesis, i.e., numbers of proliferating and of
doublecortin positive cells, in the dentate gyrus subgranular/
granular layer (data not shown). A possible explanation for
these differences is that these animals have been bred into a
genetic background different from the initial one. Further,
Monteluakst treatment had no effects on these neurogenesis
parameters, neither in WT nor in the alpha-syn animals (data
not shown).
Next, we analyzed microglia as an indicator of neuroinflam-
mation. First, we assessed the number of Iba1 positive microglia
in the hippocampus. Montelukast had no significant effects on
this parameter (Fig. 3a, b). Microglia soma size is used as mor-
phological indicator for microglia activation [35] and has been
suggested to correlate with dystrophic and dysfunctional microg-
lia [36]. Interestingly, bigger soma size is a hallmark of microglia
in aging and neurodegenerative diseases [36]. Iba1 positive mi-
croglia in the TG animals exhibited a trend towards a larger soma
size compared toWTanimals, andMontelukast treatment slight-
ly but not significantly reduced microglia soma size (Fig. 3c). To
further investigate a potential effect of Montelukast on microglia
activity, we analyzed TSPO immunoreactivity in the hippocam-
pus. TSPO, a benzodiazepine receptor (PBR) present on the
mitochondria of activated microglia, has been shown to be up-
regulated under neuroinflammatory conditions. Further, the
TSPO ligand PK11195 is used as a PET tracer to image microg-
lia and neuroinflammation in patients with neurodegenerative
disease, including patients with Lewy body pathologies [37].
TSPO immunoreactivity did, as expected, co-localize with Iba1
postive microglia (Fig. 3d). In the TG animals, TSPO immuno-
reactivity was slightly higher compared toWTanimals, but over-
all, there were no significant differences between the groups (Fig.
3e). In summary, microglia in alpha-syn TG animals showed
some minor differences compared to WT animals, and
Montelukast had only minor effects on the microglial in this
animal model. The microglia soma size did slighty but not sig-
nificantly (p= 0.0582) correlate with memory function, i.e., the
bigger the microglia cell body, the lower the performance of the
animals to memorize (Fig. 3f).
Montelukast Treatment Reduced Alpha-Synuclein
Load in the DLB Animals
Because alpha-synuclein aggregation is the typical histopatho-
logical hallmark of LBD and presented also in the alpha-syn
TG animals [25], we investigated a putative effect of
Montelukast on the alpha-synuclein load. Strong human
alpha-synuclein positive neurons were visible in the granular
cell layer of the dentate gyrus of the TG animals (Fig. 4a). In
Montelukast treated TG animals, the alpha-synuclein staining
(percentage area) in the granule cells was significantly less in-
tense compared to the vehicle treated group (Fig. 4a, b). The
number of granule cells showing the high human alpha-
synuclein load was also slightly reduced in the Montelukast
treated TG animals, although this did not reach significance
(p = 0.0622) (Fig. 4c). The reduced alpha-syn intensity showed
a strong trend for correlation with memory function (p =
0.0564) (Fig. 4d). Next, we used an antibody that specifically
detects the aggregated form of alpha-syn. Here, we did not
observe any difference in aggregated alpha-syn load between
the Montelukast and vehicle treated animals (data not shown).
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The mode of action of the Montelukast induced reduction in
the alpha-synuclein load in the TG animals is unclear at present,
but it might involve aMontelukast induced selective death of the
alpha-syuclein positive granule cells. To address this possibility,
we first analyzed the thickness of the dentate gyrus granule cell
layer in the TG animals. This parameter did not differ in
Montelukast and vehicle treated TG animals, and therefore, it is
unlikely that Montelukast induced a selective cell death of these
neurons (Supplement Figure 2). Another possibility is that
Montelukast treatment promotes autophagy. This might be of
high relevance, because impaired autophagy is central to many
neurodegenerative diseases, in particular in protein aggregation
diseases, in which impaired autophagic clearance contributes to
the accumulation of protein aggregates [38]. The two autophagy
pathways that have been implicated in synucleopathies are
macroautophagy and chaperone-mediated autophagy, which re-
quire Beclin-1 in the case of macroautophagy and LAMP2a in
the case of chaperone-mediated autophagy [39, 40]. To test
whether Montelukast treatment induces changes in autophagy,
we analyzed Beclin-1 and LAMP2a using immunohistochemis-
try. Beclin-1 immunoreactivity was similar in TG and WT ani-
mals, and the Montelukast treatment significantly elevated the
Beclin-1 expression in both genotyes (Fig. 5a, b). In contrast to
that, LAMP2a levels were higher in the TG compared to WT
animals, andMontelukast treatment did not have an effect on this
parameter (Fig. 5c, d). This suggests that Montelukast might
improve macroautophagy but not the chaperone-mediated au-
tophagy pathway.
Discussion
With the present work, we demonstrate for the first time that the
leukotriene receptor antagonist and anti-asthma medication
Fig. 3 Montelukast treatment and effects on microglia. (a) Iba1
immunostaining in the dentate gyrus of WT and alpha-syn mice treated
with vehicle or Montelukast. Insert show representative cellular
morphology. Control stainings, in which the primary goat Iba1 antibody
was omitted, excluded unspecific labelling of the secondary antibody. (b)
Number, and (c) cell soma size of Iba1 positive cells of the different
geno type and t rea tment groups . (d ) TSPO/ Iba1 doub le
immunofluorescence staining illustrating localization of TSPO primarily
in Iba1 cells. (e) Quantitative analysis of TSPO staining intensity. (f)
Correlation microglia soma size with memory. Correlations were
performed by Pearson correlation. Data are shown as mean ± SD.
*p < 0.05, **p < 0.01, ***p < 0.001. One-way ANOVA was performed
(b, c, e). Scale bars: (a) 30 μm, (d) 20 μm
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Montelukast improves memory in a synucleopathy animal
model of dementia, i.e., the human alpha-synuclein over-ex-
pressing mice. The underyling scientific rational is based on
the finding that expression of 5-Lox is elevated in DLB brains
suggesting that also leukotriene levels might be elevated in such
brains. This is most likely not specific for DLB and might play
a role also in other alpha-synucleopathies. The leukotriene re-
ceptors have been localized in the brains of MPTP mice, a
widely used acute model of dopaminergic loss [41].
CysLTR1, CysLTR2, and GPR17 are expressed in TH-
positive dopaminergic neurons and microglia, whereas
CysLTR2 expression was also found in astrocytes and was
increased after MPTP-induced damage [41]. Also, leukotrienes
contribute to vulnerability of dopaminergic neurons in response
to neurotoxicity, and leukotriene inhibition prevents MPTP-
induced death of dopaminergic neurons [41–43]. Leukotriene
receptor inhibition through Montelukast has been shown to
protect dopaminergic neurons against 6-OHDA-induced neuro-
toxicity and its administration significantly attenuated the pro-
duction of neurotoxic cytokines such as TNFalpha and IL-1beta
from activated microglia in the substantia nigra and striatum
following 6-OHDA treatment [44]. Therefore, Montelukast
Fig. 4 Montelukast reduces
alpha-synuclein in alpha-syn
mice. (a) Human alpha-synuclein
(red) and NeuN (green)
immunostainings in TG mice
treated with vehicle or
Montelukast. Note the strong
human alpha-synuclein positive
accumulation in the granular cell
layer of the dentate gyrus of the
vehicle treated TG animals, which
was hardly detected in the
Montelukast treated animals. (b)
Quantitative analysis of the
percentage area of the staining
confirmed the lower levels of
alpha-syn in the Montelukast
treated group. (c) Number of
human alpha-syn positive
neuronal cell bodies in the dentate
gyrus granular cell layer. (d)
Correlation %Area aSyn with
memory. Correlation was
performed by Pearson correlation.
Data are shown as mean ± SD.
*p < 0.05, **p < 0.01,
***p < 0.001. Unpaired Student’s
t test was performed (b, c). Scale
bars, 25 μm
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might be a potential drug candidate not only in DLB but also in
other synucleophaties. This is further supported by a recent
study demonstrating that salbutamol, a brain-penetrant asthma
medication, is associated with reduced risk of developing
Parkinson’s disease [45].
Besides in synucleopathy-related disorders, the leukotriene
system might be a relevant drug target in various other neuro-
degenerative diseases such as AD (for review see [15]), in
acute CNS lesions such as stroke [24] and spinal cord injury
[46, 47], and in a variety of other non-CNS chronic diseases
[48]. For example, overexpression of ALOX5, the gene
encoding 5-Lox resulted in increased amyloid β plaque for-
mation, increased levels of γ-secretases and increased levels
of total tau and phosphorylated tau in the 3xTG mouse model
of AD [49]. Vice versa, an ALOX5 knock-out mediated defi-
ciency of 5-Lox reduced the levels of amyloid beta and its
depositions in the brain of Tg2576 AD mice [50]. Similarly,
deletion of ALOX5, the gene encoding 5-Lox, leads to
memory improvement and enhanced synaptic integrity, and
to a reduction in amyloid beta and tau pathology in transgenic
AD mice [51]. Besides genetic approaches, pharmacologic
targeting of leukotriene synthesis and of leukotriene receptors
has been shown to modulate disease pathology and improve
cognitive functions in animal models of AD and in aged wild-
type rodents. For example, Zileuton, a specific 5-Lox inhibi-
tor, reduced amyloid beta levels and plaque deposition and the
levels of insoluble and of hyperphosphorylated tau, and stabi-
lized or improved cognitive function in animal models of
Alzheimer’s disease [52–54]. In the MCAO model of stroke,
leukotriene receptor blockade through Montelukast reduced
lesion size progression, improved fiber connectivity and func-
tional recovery [24].
What is the mode of action of leukotriene or leukotriene
receptor antagonization? As recently reviewed [15], leukotriene
signaling can contribute to neuroinflammation, neurodegenera-
tion, BBB disruption, and to impairment in neurogenesis.
Fig. 5 Montelukast affects autophagy markers in alpha-syn mice. (a)
Immunofluorescence of Beclin-1 (green) and NeuN (violet) in the
granular cell layer of the dentate gyrus/hippocampus in alpha-syn
transgenic mice treated with vehicle or Montelukast. Note the more
intense staining in the Montelukast treated group. (b) Quantitative
analysis of the Beclin-1 staining intensity. (c) Immunofluorescence
images of Lamp2A (green) and NeuN (violet) in the granular cell layer
of the dentate gyrus/hippocampus in alpha-syn transgenic mice treated
with vehicle or Montelukast. (d) Quantitative analysis of the Lamp2A
staining intensity. Data are shown as mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.001. One-way ANOVA followed by Tukey’s post hoc test was
performed. Scale bars, 20 μm
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Although in aged rats the Montelukast induced learning and
memory improvements correlated with increased neurogenesis
[19], we did not observe any neurogenesis boosting effects by
Montelukast in the alpha-syn TG animals nor in the WT ani-
mals. This, however, might be due to the fact that i)
neurogenesis was not affected in the TG mice compared to
WTanimals, and ii) animals, alsoWT, were of relatively young
age (6–7.5 months), in which neurogenesis has not yet declined
[55]. Thus, Montelukast improved cognition in the alphy-syn
animals most likely in a neurogenesis independent mode of
action. As in our recent aging study [19], we did observe mod-
erate, although not significant, Montelukast treatment-induced
changes in microglia. This might be of relevance because a
broad body of evidence highlighted that neuroinflammation is
central in alpha-synucleopathies such as LBD (for review see
[13]). Moreover, in synucleopathies, like in many other neuro-
degenerative diseases, microglia are the brain’s most relevant
resident innate immune cells [14]. Nevertheless, the possible
effects of Montelukast on neuroinflammation and on microglia
certainly require further in-depth analysis, considering also the
very recent developments on gene expression profiling of mi-
croglia phenotypes at the single cell level [56, 57]. The latter
has underscored the heterogeneity of microglia in the brain and
identified a signature for degeneration associated microglia.
Further, Montelukast might, and we cannot exclude this at the
moment, exert its effects on the CNS and on neuroinflammation
via modulating the peripheral immune system. Indeed, there is
ample evidence for anti-inflammatory effects of Montelukast in
peripheral tissues and organs. Montelukast treatment reduces
production of IL-6, IL-8, GM-CSF, INF-gamma, RANTES,
TNF-alpha, CRP, and CCL-2 [58–68] and elevates the levels
of the anti-inflammatory cytokine IL-10 [69]. Of importance,
inflammatory cytokines and inflammation in serum correlate
with disease progression of PD and PDD. PD patients have
elevated levels of CRP, CCL-2, IL-6, and of TNF-alpha, corre-
lating partially with fatigue, depression and anxiety, and with
cognitive deficits [70–72]. Moreover, the levels of cytokines
and chemokines (CCL-2, RANTES, MIP-1alpha, IL-8,
IFNgamma, IL-1beta and TNFalpha) produced by peripheral
blood mononuclear cells (PBMCs) derived from PD patients
are significantly elevated [73]. Obviously, in cases where
Monteluakst might reduce neuroinflammation, an optimal
timing of treamtnet might be crucial. For example, early treat-
ment of neurodegenerative diseases might potentiate the effects
of Montelukast. This has been suggested in a Norwegian retro-
spective analysis of a drug prescription database, the
Norwegian Prescription Database (NorPD), in which people
elder than 50 that have been prescribedMontelukast were com-
pared to people prescribed inhalative corticosteroids. The con-
clusion was that the Montelukast group had a significant lower
probability of requiring a dementia drug later in life and of
requiring to be placed in a nursing home [74]. Another aspect
might be the potential of Monteluakst to affect, besides
cognition and memory, other non-motor sympotms of
synucleopathies such as depression [75]. The latter is generally
associated with neuroinflammation [76]. Also, of note, there is
a strong comorbidity between DLB and depression [77].
An unexpected and novel finding of the present work
was that Montelukast treatment induced reduction in the
alpha-synulcin load in the dentate gyrus. The analysis of
autophagy markers suggests that Montelukast might re-
store autophagy in the alpha-syn mice. The underlying
mode of action is unknown, as the effects of leukotrienes
and of leukotriene inhibition on autophagy are rather un-
explored [78, 79]. Nervertheless, this might be of huge
importance, as in synucleopathies as well as in other neu-
rodegenerative diseases autophagy is typically impaired,
and restoration of autophagy is discussed as a potential
therapeutic strategy. There is a strong body of evidence
that in synucleinopathies the clearance of toxic synuclein
is impaired, contributing to neurodegeneration (for re-
view, see [80]). In PD and LBD mouse models and trans-
genic cell lines, dysfunctional lysosomes were shown to
impair the autophagy process, which resul ted in
autophagosome accumulations in neurons [80]. The pu-
tative effect of Montelukast on autophagy certainly re-
quires further investigations. A higher expression of
beclin-1 might indicate an improved macroautophagy.
Also, the unchanged levels of Lamp2a suggest that
chaperone-medicated autophagy is not a l terend.
However, because there is a strong crosstalk between
these two forms of autophagy, in particular in neurode-
generative diseases [81], we cannot really differentiate
between a possible regulation of macro- and chaperone-
mediated autophagy. Nevertheless, autophagy as a pos-
sible mode of action of Montelukast would certainly ex-
tend the use of this drug to many degenerative diseases
that involve dysregulation of autophagy.
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